BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 14-Nov-2019

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 17.11.2019 to 18.11.2019. Trading of the shares of the Company will remain suspended on record date i.e., 19.11.2019.

SQURPHARMA 14-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 4.25 for July-September 2019 as against Tk. 4.02 for July-September 2018; Consolidated NOCFPS was Tk. 4.14 for July-September 2019 as against Tk. 4.06 for July-September 2018. Consolidated NAV per share was Tk. 90.00 as on September 30, 2019 and Tk. 86.03 as on June 30, 2019.

SQURPHARMA 07-Nov-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2019 at 3.00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.

SQURPHARMA 23-Oct-2019

There will be no price limit on the trading of the shares of the Company today (23.10.2019) following its corporate declaration.

SQURPHARMA 23-Oct-2019

(Continuation news of SQURPHARMA): ii) Bonus share is declared out of accumulated profit. iii) Bonus share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post dividend retained earnings become negative or a debit balance. (end)

SQURPHARMA 23-Oct-2019

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 16.03, Consolidated NAV per share of Tk. 86.03 and Consolidated NOCFPS of Tk. 15.71 for the year ended on June 30, 2019 as against Tk. 14.69, Tk. 73.28 and Tk. 12.55 respectively for the same period of the previous year. The Company also informed that i) Bonus shares has been recommended in view to utilize its retained amount as capital for business expansion. (cont.2)

SQURPHARMA 23-Oct-2019

The Board of Directors has recommended 42% cash and 7% stock dividend for the year ended on June 30, 2019. The Board has also approved Tk. 200.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 12.12.2019, Time: 10:00 AM, Venue: Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date: 19.11.2019. (cont.1)

SQURPHARMA 10-Oct-2019

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2019 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.

SQURPHARMA 29-Apr-2019

(Q3 Un-audited): Consolidated EPS was Tk. 3.95 for January-March 2019 as against Tk. 3.77 for January-March 2018; Consolidated EPS was Tk. 11.93 for July 2018-March 2019 as against Tk. 11.20 for July 2017-March 2018. Consolidated NOCFPS was Tk. 11.34 for July 2018-March 2019 as against Tk. 10.52 for July 2017-March 2018. Consolidated NAV per share was Tk. 81.95 as on March 31, 2019 and Tk. 73.28 as on June 30, 2018.

SQURPHARMA 23-Apr-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2019.

Previous Next page